What is Regen® ATS?

The Regen® ATS tube facilitates rapid preparation of an Autologous Thrombin Serum at point-of-care, simultaneous to the preparation of Leukocyte-Poor A-PRP® (RegenPlasma®) utilizing Regen® BCT.

The combination of Regen® BCT and Regen® ATS offers a host of possibilities.  With the addition of autologous thrombin serum to a liquid PRP, a platelet-rich fibrin gel can be achieved.

Should a provider feel it is necessary, ratio may be adjusted at their discretion, such that platelet-rich gels of varying strengths and rigidity may be achieved.

In this way, a provider can make their expert determination regarding how best to meet their patient’s individual needs, achieving the optimal state and shape for the respective situation.

The result is a feat of tissue engineering:  prepared at point of care and fully biocompatible with the patient from which the blood was drawn, which can also be used as a dimensionally stable membrane if required.


Intended Use of the Device:  All models of RegenKit®-BCT Plus are designed to be used for the safe and rapid preparation of autologous platelet-rich plasma (PRP) and autologous serum from a small sample of blood at the patient’s point of care. The combined PRP and autologous serum are mixed with autograft and/or allograft bone prior to application to a bony defect for improving handling characteristics.

The RegenKit®-BCT Plus Family Kits are for single use only.



Instructions for Use (IFU):


IFU – RegenKit BCT-2 Plus (10 mL)


RegenKit® BCT-2 Plus

RegenKit BCT-2 Plus has the capability to prepare a fully autologous platelet-rich gel from a 30 mL Blood Draw, 2 x 10 mL tubes for PRP preparation, and the third 10 mL tube for preparation of autologous thrombin serum.  Each Regen® BCT tube generates roughly 5-6 mL of RegenPlasma® | Leukocyte-Poor A-PRP®.

Platelet-Rich Gel Explanation:  The addition of autologous thrombin serum (ATS) to the RegenPRP™ begins the coagulation process on a physiological level.  Autologous Thrombin Serum (ATS) converts soluble fibrinogen into fibrin monomers, which polymerize into a clot.
This natural process induces the formation of a three-dimensional fibrin matrix in which the platelets are embedded. This enables long-lasting growth factor delivery at the treatment site and the matrix serves as a scaffold for new tissue reconstruction.
The coagulation process is a complex cascade of reactions that causes the thrombin to convert soluble fibrinogen into insoluble fibrin molecules that form the fibrin clot. If calcium is added, this accelerates the process and the fibrin structure is strengthened.


Technology Platform for Standardized Autologous Regenerative Medicine

simple, safe and efficient point-of-care preparation of autologous platelet-rich plasma






  • Standardized preparation
  • Minimum Blood Requirements
  • Closed-Loop System:  maximized safety
  • Stable Physical Separation
  • Reversible, Pharmaceutical-Grade Anticoagulation
  • pH Neutral Anticoagulant for Patient Tolerability
  • Rapid Centrifugation: 5 minutes
  • Ease of Preparation:  efficient & reproducible
  • Facilitates and streamlines routine practice



  • Demonstrated safety and efficacy
  • Evidence-based outcomes for numerous therapeutic indications
  • Large number of clinical studies, with over 200 publications


  • Standardized, Leukocyte-Poor, and Consistent
  • Platelet Recovery >80%
  • High Platelet Quality: viability & functionality
  • Full Plasma Recovery:  maximized Growth factor and fibrinogen content
  • Maximized Purity:  >99.7% RBC depletion
  • Extreme Cellular Selectivity:  ~96.5% GRN & 70-80% MNC elimination

Regen® BCT

Standardized Performance.  Cellular Selectivity

Available in both 10 mL and 20 mL Kits.

Regen® Innovative Preparation methods, combined with the “GMP Lab in a Tube” and the Regen® A-PRP® Cellular Selectivity Model, facilitate an efficient and consistent preparation which allows a provider to choose the preparation which best fits their individual patient’s needs.

   RegenPlasma®Leukocyte-Poor A-PRP® 

                      Regen® BCT  |  Concentration Flexibility                


Regen®  |  Innovative Preparations

Filter by:
RegenKit® Wound Gel
RegenKit® THT®
Regen® Spray Applicator

RegenKit® BCT -2 Plus



RegenKit® BCT-2 Plus (10 mL)   |   RK-BCT-2A 


2  Regen® BCT 10 mL Tubes

1 Regen® ATS 10 mL Tube

1 Safety–Lok™ Butterfly needle
1 Collection holder
1 Transfer device
2 transfer needles
2  5 mL Luer-Lok™ syringes


Blood Draw Accessories Compatible with 10 mL and 20 mL

RegenKit® Medical Devices are available for your convenience,

and are highly recommended to maximize preparation efficiency.





Warnings and precautions

Strict aseptic technique must be followed during the whole procedure. Use proper safety precautions to avoid contact with patient blood or cross-contamination. Use proper safety precautions to protect against needles or broken tubes. Do not use sterile component of this kit if it is opened or damaged. Do not use components of this kit if they are broken or present a defect. Do not use the tube if it has lost vacuum. Do not use the sodium citrate solution or other tube components separately. Store between 5 ºC and 30ºC; bring the kit to ambient temperature before using tubes. Do not re-sterilise, do not use after the expiration date. Single use device, do not reuse any part of the kit. Reuse may lead to infection or other illness / injury. Transfer needle must be used to transfer liquids only and should not be used for injection. The preparation of the platelet-rich plasma (PRP) must be performed by a physician trained on the equipment and procedure, or under the supervision of the physician. The treatment with PRP must be performed by a qualified physician. Do not inject PRP intravascularly. The patient must be informed of the general risks associated with the treatment and of the possible adverse effects. The safety and effectiveness of combination of PRP with other therapies should be assessed by the physician. The safety and effectiveness have not been evaluated in children and in pregnant or lactating women. The PRP must be prepared from fresh blood and must be used within four hours (extemporaneous use only).

All tubes and components of the kit are to be entirely discarded by elimination method after each use to avoid potential contamination with blood products. Use a 45° fixed angle rotor centrifuge or a horizontal head swinging bucket centrifuge (ex. RegenPRP Centri provided by Regen Lab). Follow the manufacturer’s instructions when using the centrifuge. Tubes should be centrifuged, as recommended in the instructions for use, at a relative centrifugation force (RCF) of 1500 g. Excessive RCF (over 2200 g) may lead to tube breakage resulting in blood exposure, and possible injury. RCF below 1500 g may lead to incorrect blood separation and red blood cell contamination of PRP. Centrifuge carriers and inserts size should be adapted to the tubes. Use of carriers too large or too small may result in breakage of the tubes. Caution should be taken to ensure that tubes are properly seated in the centrifuge carriers. Tubes must be balanced in the centrifuge.


Possible adverse effects


Possible side effects of blood collection

Blood collection may cause damage of the blood vessels, hematomas, superficial phlebitis, delayed wound healing, early or late infection and/or temporary or permanent nerve damage that may result in pain or numbness.

Patent Protected
Regen Lab SA

U.S., European, and Swiss

Patent Listings

RegenLab®, RegenKit®, Regen®, A-PRP®, & RegenPlasma®
are U.S. registered trademarks of RegenLab USA and/or Regen Lab SA

Contact Regenlab® USA


Now is the time to step into the future of medicine.

Join the Generation! 

| REGENeration |


Get connected with us to Learn More.

For more information on our products, please contact us by clicking on the button below:


Our Affiliated Locations:

  • New York (USA)
  • Montréal (Canada)
  • Venice (Italy)
  • Munich (Germany)
  • Paris (France)
  • Dubai (U.A.E.)
  • Beijing (China)
  • Istanbul (Turkey)